ALLOGENIC BONE-MARROW TRANSPLANTATION IN PATIENTS WITH MALIGNANT HEMATOLOGICAL DISEASES

We have treated 28 patients (pts) with malignant henmatological diseas es with allogeneic bone marrow transplantation (BMT). 28 pls had acute lymphoblastic (ALL) and non lymphoblastic leukemia (ANLL) 5 chronic m yeloid leukemia (CML), 2 severe aplastic anemia (SAA), 1 myelodisplasi a, 1 Fanconi's anemia and 1 advanced Non Hodgkin's lymphoma. All but t hree received the graft from HLA identical sibling donors. We used con ditioning with total body irradiation and chemotherapy (cyclophosphami de, cytarabine and etoposide) in 17 pts and chemotherapy alone in 11. 24 Pts had full hematological recovery 18 to 25 days Post BMT. 15 pts died after BMT as a consequence of toxicity or early infection (4), gr aft failure (2), graft versus host disease (4) or relapse (5). Actuari al event free survival for the group with favorable prognosis (SAA, AL L and ANLL in first or second remission and CML in chronic phase) is 5 7% at 36 months. Allogeneic BMT is an effective and feasible therapeut ic procedure for selected patients with hematological malignancies.